Heart rhythm O2 · 2026
Safety and efficacy of ultralow-dose fluoroscopy in left atrial appendage occlusion.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Demian Joe, Younis Arwa, El Hajjar Abdel Hadi, Kanj Mohamed, Saliba Walid I, Santangeli Pasquale, Tabaja Chadi, Baranowski Bryan, Taigen Tyler L, Bhargava Mandeep, Wazni Oussama M, Hussein Ayman A
Аннотация
BACKGROUND: Minimizing radiation exposure has become a growing priority in electrophysiology, with increasing adoption of zero- or minimal-fluoroscopy techniques. Little is known about left atrial appendage occlusion (LAAO) using ultralow-dose fluoroscopy.
OBJECTIVE: This study aimed to assess the safety and efficacy of an ultralow-dose fluoroscopy strategy for LAAO.
METHODS: In a prospectively maintained registry at our center, 46 patients underwent LAAO with ultralow-dose fluoroscopy using Watchman FLX devices (Boston Scientific, Minneapolis, MN). The ultralow-dose strategy was a priori planned for these patients with the goal of minimizing radiation exposure (total radiation exposure <10 mGy), while relying on transesophageal echocardiography guidance for device placement. The ultralow-dose fluoroscopy group was compared using propensity score matching with patients treated with standard fluoroscopy guidance (1:3 matching; n = 46 vs 138). Baseline characteristics, procedural metrics, and clinical outcomes were compared between groups.
RESULTS: Procedural success was 100% in both groups, with significantly shorter procedural duration in the ultralow-dose group (42 vs 60 minutes; P < .001). Periprocedural adverse events were infrequent and did not differ significantly (none in ultralow dose vs 3 cases [2.2%] in standard dose; P = .6). Closure success at 45 days was high in both groups (97.8% vs 100%; P = .3). Device-related thrombus occurred in 1 ultralow-dose patient (2.2%)-with none in the standard group (P = .3)-and resolved without sequelae with anticoagulation. The 1-year rate of ischemic stroke or systemic embolism was similarly low between groups, with 2 (4.3%) vs 3 events (2.2%), respectively (P = .4).
CONCLUSION: Ultralow-dose fluoroscopy is a safe and effective, radiation-sparing strategy for LAAO.
OBJECTIVE: This study aimed to assess the safety and efficacy of an ultralow-dose fluoroscopy strategy for LAAO.
METHODS: In a prospectively maintained registry at our center, 46 patients underwent LAAO with ultralow-dose fluoroscopy using Watchman FLX devices (Boston Scientific, Minneapolis, MN). The ultralow-dose strategy was a priori planned for these patients with the goal of minimizing radiation exposure (total radiation exposure <10 mGy), while relying on transesophageal echocardiography guidance for device placement. The ultralow-dose fluoroscopy group was compared using propensity score matching with patients treated with standard fluoroscopy guidance (1:3 matching; n = 46 vs 138). Baseline characteristics, procedural metrics, and clinical outcomes were compared between groups.
RESULTS: Procedural success was 100% in both groups, with significantly shorter procedural duration in the ultralow-dose group (42 vs 60 minutes; P < .001). Periprocedural adverse events were infrequent and did not differ significantly (none in ultralow dose vs 3 cases [2.2%] in standard dose; P = .6). Closure success at 45 days was high in both groups (97.8% vs 100%; P = .3). Device-related thrombus occurred in 1 ultralow-dose patient (2.2%)-with none in the standard group (P = .3)-and resolved without sequelae with anticoagulation. The 1-year rate of ischemic stroke or systemic embolism was similarly low between groups, with 2 (4.3%) vs 3 events (2.2%), respectively (P = .4).
CONCLUSION: Ultralow-dose fluoroscopy is a safe and effective, radiation-sparing strategy for LAAO.